ZLNA — Zelluna ASA Share News
0.000.00%
Last trade - 00:00- NOK544.15m
- NOK451.38m
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant
Brief: Zelluna: Phase II Dovacc Trial Of UVI Cancer Vaccine Does Not Meet Primary Endpoint
Brief: Zelluna Raises NOK 58 Mln In New Share Offering
Brief: Zelluna Launches Private Placement, Retail Offer
Brief: Zelluna Expexts Current Cash Position To Support Operations Into Q1 2027
Brief: Zelluna ASA Activates First Clinical Site For Zima-101, Marking Entry Into Clinical Execution
Brief: Zelluna: Collaboration With Etcembly For AI-Enabled TCR Engineering
Brief: Zelluna Q4 Total Loss At NOK 34.6 Million
Brief: Zelluna Announces Clinical Partnership With Medpace
Brief: Zelluna Submits Clinical Trial Application In The UK For First-In-Human Study Of Zi-Ma4-1
Brief: Zelluna Announces Preclinical Data For Lead Candidate Zi-Ma4-1
Brief: Zelluna Completes First GMP Batch Of ZI-MA4-1
Brief: Zelluna Cancels Subsequent Offering
Brief: Zelluna Q3 Operating Loss Widens To NOK 39.7 Million
Brief: Zelluna Receives Positive Feedback From UK's MHRA
Brief: Zelluna Q2 Total Operating Expenses NOK 38.4 Mln